[go: up one dir, main page]

GB1171125A - Improvements in or relating to Injectable Preparations - Google Patents

Improvements in or relating to Injectable Preparations

Info

Publication number
GB1171125A
GB1171125A GB25595/66A GB2559566A GB1171125A GB 1171125 A GB1171125 A GB 1171125A GB 25595/66 A GB25595/66 A GB 25595/66A GB 2559566 A GB2559566 A GB 2559566A GB 1171125 A GB1171125 A GB 1171125A
Authority
GB
United Kingdom
Prior art keywords
aqueous phase
clostriduim
materials include
polyoxyethylene derivative
injectable preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB25595/66A
Inventor
Clive Anthony Walton
Clarence Leonard James Coles
Ernst Ludwig Neustadter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Laboratories Ltd
Original Assignee
Glaxo Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Laboratories Ltd filed Critical Glaxo Laboratories Ltd
Priority to GB25595/66A priority Critical patent/GB1171125A/en
Priority to US642727A priority patent/US3384544A/en
Priority to NL6707702.A priority patent/NL159283B/en
Priority to IT37275/67A priority patent/IT1035004B/en
Priority to DE19671617502 priority patent/DE1617502C/en
Priority to BE699678D priority patent/BE699678A/xx
Priority to FR119939A priority patent/FR7316M/fr
Publication of GB1171125A publication Critical patent/GB1171125A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

1,171,125. Vaccines; injectable preparations. GLAXO LABORATORIES Ltd. 31 May 1967 [8 June, 1966], No. 25595/66. Heading A5B. An injectable preparation comprises an aqueous phase associated with microorganisms and/or physiologically active, high molecular weight materials (e.g. proteins, polysaccharides or nucleic acids), the said aqueous phase being solubilised in a physiologically acceptable lipophilic medium by means of one or more non-ionic, amphiphilic, surface active agents, e.g. a fatty acid ester of a sugar alcohol anhydride, an ethylene oxide condensatethereof, a polyoxyethylene derivative of an alkyl phenol or a polyoxyethylene derivative of a fatty alcohol. A surface liquidising, agent e.g. a C 3-10 alkanol may also be present. Suitable lipophilic materials include paraffin oil, squalane, vegetable oils, tridecyl myristate and n-octyl oleate. The aqueous phase is present dispersed in the oil phase as particles sufficiently small (e.g. 50 to 800Š) for the preparation to be optically clear. Specified active materials include Clostriduim welchii; C. tetani; C. septicum; C. chauvoei; Brucella abortus, Infectious bronchitis virus; B. pertussis and Clostriduim oedematiens toxoids.
GB25595/66A 1966-06-08 1966-06-08 Improvements in or relating to Injectable Preparations Expired GB1171125A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GB25595/66A GB1171125A (en) 1966-06-08 1966-06-08 Improvements in or relating to Injectable Preparations
US642727A US3384544A (en) 1966-06-08 1967-06-01 Injectable solutions or suspensions of antigens in optically clear colloidal solutions
NL6707702.A NL159283B (en) 1966-06-08 1967-06-02 PROCESS FOR PREPARING AN INJECTABLE PREPARATION.
IT37275/67A IT1035004B (en) 1966-06-08 1967-06-06 INJECTABLE WATER COMPOSITION AND PROCEDURE FOR PREPARING IT
DE19671617502 DE1617502C (en) 1966-06-08 1967-06-08 Injectable Compositions
BE699678D BE699678A (en) 1966-06-08 1967-06-08
FR119939A FR7316M (en) 1966-06-08 1967-09-05

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB25595/66A GB1171125A (en) 1966-06-08 1966-06-08 Improvements in or relating to Injectable Preparations

Publications (1)

Publication Number Publication Date
GB1171125A true GB1171125A (en) 1969-11-19

Family

ID=10230237

Family Applications (1)

Application Number Title Priority Date Filing Date
GB25595/66A Expired GB1171125A (en) 1966-06-08 1966-06-08 Improvements in or relating to Injectable Preparations

Country Status (6)

Country Link
US (1) US3384544A (en)
BE (1) BE699678A (en)
FR (1) FR7316M (en)
GB (1) GB1171125A (en)
IT (1) IT1035004B (en)
NL (1) NL159283B (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0059521A1 (en) * 1981-03-03 1982-09-08 Centraal Diergeneeskundig Instituut Water-in-oil emulsion for use in the potentation of the immune system of animals
EP0202837A1 (en) * 1985-05-17 1986-11-26 Smithkline Beckman Corporation Polyene antibiotic emulsion formulation
WO1992018147A1 (en) * 1991-04-19 1992-10-29 Affinity Biotech, Inc. Convertible microemulsion formulations
WO1994008610A1 (en) * 1992-10-16 1994-04-28 Smithkline Beecham Corporation Pharmaceutical emulsion compositions
WO1994017827A1 (en) * 1993-02-15 1994-08-18 Lyfjathroun H.F. A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
US5741512A (en) * 1988-09-16 1998-04-21 Novartis Corporation Pharmaceutical compositions comprising cyclosporins
US5989566A (en) * 1995-06-30 1999-11-23 American Cyanamid Company Stable vaccine compositions for parenteral administration, a method for their use, and a process for their preparation
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US6214367B1 (en) 1996-06-05 2001-04-10 Ashmont Holdings Limited Injectable compositions
US6245349B1 (en) 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US6258808B1 (en) 1991-06-27 2001-07-10 Novartis Ag Pharmaceutical composition
US6420355B2 (en) 1992-09-25 2002-07-16 Novartis Ag Pharmaceutical compositions containing cyclosporins
US6475519B1 (en) 1997-01-30 2002-11-05 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin A
US6486124B2 (en) 1994-11-03 2002-11-26 Novartis Ag Cyclosporin compositions and process therefor
US6582718B2 (en) 1992-05-13 2003-06-24 Novartis Ag Cyclosporin compositions
US6951841B2 (en) 1995-11-29 2005-10-04 Novartis Ag Pharmaceutical compositions of macrolides or cyclosporine with a polyethoxylated saturated hydroxy-fatty acid
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3678149A (en) * 1970-01-26 1972-07-18 Samuel J Prigal Method of enhancing the action of a medicament
AU2629871A (en) * 1970-03-17 1972-09-14 Merck & Co., Inc Solubilization of water and aqueous solutions in non-aqueous liquids
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
JPS53107408A (en) * 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
US4530832A (en) * 1978-12-07 1985-07-23 Schering Corporation Method of vaccination for prevention of Bordetella bronchiseptica infection
FR2501526A1 (en) * 1981-03-13 1982-09-17 Montagne Noire Produits Chimiq Emulsifier for veterinary oily vaccine prodn. - is alkoxylated oleic acid ester of mannitol dehydration prod.
JP3609827B2 (en) * 1991-06-26 2005-01-12 ヤマノウチ ユーロープ ベスローテン フェンノートシャップ Vesicles in nonpolar bases
WO1999021533A2 (en) * 1997-10-24 1999-05-06 Neorx Corporation Delivery vehicles for bioactive agents and uses thereof
US8703095B2 (en) * 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE25721E (en) * 1965-01-26 Swine erysipelas vaccine
US2966443A (en) * 1959-06-22 1960-12-27 American Cyanamid Co Trivalent poliomyelitis live virus vaccine
US3099601A (en) * 1959-10-02 1963-07-30 Anchor Serum Company Bacterin in aqueous polyethylene, mineral oil emulsion
US3096249A (en) * 1960-05-10 1963-07-02 Samuel J Prigal Emulsion composition
GB914894A (en) * 1960-08-12 1963-01-09 Beecham Res Lab Injectable pharmaceutical media
US3149036A (en) * 1961-10-16 1964-09-15 Merck & Co Inc Adjuvant vaccine with aluminum monostearate, mannide monooleate, vegetable oil, and an aqueous phase immunolgical agent
US3185625A (en) * 1961-11-08 1965-05-25 Brown Ethan Allan Injectionable substances

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0059521A1 (en) * 1981-03-03 1982-09-08 Centraal Diergeneeskundig Instituut Water-in-oil emulsion for use in the potentation of the immune system of animals
EP0202837A1 (en) * 1985-05-17 1986-11-26 Smithkline Beckman Corporation Polyene antibiotic emulsion formulation
US5866159A (en) * 1988-09-16 1999-02-02 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US7235248B2 (en) 1988-09-16 2007-06-26 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US6024978A (en) * 1988-09-16 2000-02-15 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US5962014A (en) * 1988-09-16 1999-10-05 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US5962017A (en) * 1988-09-16 1999-10-05 Novartis G Pharmaceutical compositions comprising cyclosporins
US5916589A (en) * 1988-09-16 1999-06-29 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US5741512A (en) * 1988-09-16 1998-04-21 Novartis Corporation Pharmaceutical compositions comprising cyclosporins
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
WO1992018147A1 (en) * 1991-04-19 1992-10-29 Affinity Biotech, Inc. Convertible microemulsion formulations
US5633226A (en) * 1991-04-19 1997-05-27 Lds Technologies, Inc. Convertible microemulsion formulations
US5444041A (en) * 1991-04-19 1995-08-22 Ibah, Inc. Convertible microemulsion formulations
US5646109A (en) * 1991-04-19 1997-07-08 Lds Technologies, Inc. Convertible microemulsion formulations
US6844459B2 (en) 1991-06-27 2005-01-18 Novartis Ag Pharmaceutical Composition
US6258808B1 (en) 1991-06-27 2001-07-10 Novartis Ag Pharmaceutical composition
US6582718B2 (en) 1992-05-13 2003-06-24 Novartis Ag Cyclosporin compositions
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
US6420355B2 (en) 1992-09-25 2002-07-16 Novartis Ag Pharmaceutical compositions containing cyclosporins
WO1994008610A1 (en) * 1992-10-16 1994-04-28 Smithkline Beecham Corporation Pharmaceutical emulsion compositions
WO1994017827A1 (en) * 1993-02-15 1994-08-18 Lyfjathroun H.F. A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
US5942237A (en) * 1993-02-15 1999-08-24 Lyfjathroun H.F. Pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
US6486124B2 (en) 1994-11-03 2002-11-26 Novartis Ag Cyclosporin compositions and process therefor
US5989566A (en) * 1995-06-30 1999-11-23 American Cyanamid Company Stable vaccine compositions for parenteral administration, a method for their use, and a process for their preparation
US6951841B2 (en) 1995-11-29 2005-10-04 Novartis Ag Pharmaceutical compositions of macrolides or cyclosporine with a polyethoxylated saturated hydroxy-fatty acid
US6245349B1 (en) 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US6214367B1 (en) 1996-06-05 2001-04-10 Ashmont Holdings Limited Injectable compositions
US6663879B2 (en) 1996-06-05 2003-12-16 Ashmont Holdings Limited Injectable compositions
US6475519B1 (en) 1997-01-30 2002-11-05 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin A
US6723339B2 (en) 1997-01-30 2004-04-20 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin A
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin

Also Published As

Publication number Publication date
NL6707702A (en) 1967-12-11
DE1617502A1 (en) 1972-02-10
IT1035004B (en) 1979-10-20
US3384544A (en) 1968-05-21
FR7316M (en) 1969-10-06
BE699678A (en) 1967-12-08
NL159283B (en) 1979-02-15

Similar Documents

Publication Publication Date Title
GB1171125A (en) Improvements in or relating to Injectable Preparations
Jennings Review of selected adjuvants used in antibody production
Aucouturier et al. Adjuvants designed for veterinary and human vaccines
NL194603C (en) Immunological adjuvant.
AU2007204295A1 (en) Thermoreversible oil-in-water emulsion
Nowotny RELATION OF STRUCTURE TO FUNCTION IN BACTERIAL O ANTIGENS II: Fractionation of Lipids Present in Boivin-Type Endotoxin of Serratia marcescens
JPH07509733A (en) Water-in-oil vaccine liquid emulsion containing metabolizable oil
EP4098250A1 (en) Microemulsion-based vaccine delivery system, preparation method therefor and use thereof
Evans et al. Antitumor Immunity in the Shope Papilloma-Carcinoma Complex of Rabbits. Ill. Response to Reinfection With Viral Nucleic Acid
TW577746B (en) Method to produce inactivated w/o emulsion adjuvated vaccines
US3920811A (en) Adjuvant compositions
EP3389698B1 (en) Dried composition
McLaughlin et al. Tumor regression induced by defined microbial components in an oil-in-water emulsion is mediated through their binding to oil droplets
Hyslop et al. The influence of aluminium hydroxide content, dose volume and the inclusion of saponin on the efficacy of inactivated foot-and-mouth disease vaccines
CN113679831A (en) An oil-in-water emulsion mucosal vaccine for injection and its preparation method and application
Schoenberg et al. The cellular response of the spleen and its relationship to the circulating 19S and 7S antibody in the antigenically stimulated rabbit
O'Toole et al. Iatrogenic compressive lumbar myelopathy and radiculopathy in adult cattle following injection of an adjuvanted bacterin into loin muscle: histopathology and ultrastructure
Stalheim Viable, avirulent Leptospira interrogans serotype pomona vaccine: Preservation in liquid nitrogen
GB1152607A (en) Antigenic Compositions
DE2756851A1 (en) ADJUVANTIES OF NON-SPECIFIC IMMUNITY
Wisseman Jr Interaction of Rickettsiae and Phagocytic Host Cells: II. Chemotactic Action of Typhus Rickettsiae on Human Polymorphonuclear Leukocytes in Vitro
Herbert et al. Field trials of adjuvant and saline influenza vaccines
KR940008695A (en) Antithrombin III Preparation
Madera et al. Development of a Self-Emulsifying Adjuvant for Use in Swine Vaccines
Woodward et al. Suppression of chick pancreatic xanthine dehydrogenase by unsaturated fatty acids